Literature DB >> 11283936

Expression and prognostic significance of catalase in malignant mesothelioma.

K Kahlos1, Y Soini, R Sormunen, R Kaarteenaho-Wiik, P Pääkkö, K Linnainmaa, V L Kinnula.   

Abstract

BACKGROUND: Free radicals and antioxidant enzymes (AOEs) may play a critical role in cell proliferation and in the resistance of malignant cells against cytotoxic drugs and radiation. Malignant mesothelioma is a resistant tumor with high levels of manganese superoxide dismutase, a central superoxide scavenging AOE. In the current study, the authors assessed the expression and prognostic role of catalase, an important hydrogen peroxide scavenging AOE, in malignant pleural mesothelioma.
METHODS: Catalase expression was investigated by immunohistochemistry in 5 cases of nonmalignant healthy pleura and in tumor tissue of 32 mesothelioma patients, and by Western blot in 7 continuous human mesothelioma cell lines. The distribution of catalase in mesothelioma cells was assessed by immunoelectron microscopy. Furthermore, to investigate the effect of catalase inhibition in the drug resistance of these cells in vitro, the authors exposed mesothelioma cells with the highest catalase level to epirubicin with and without aminotriazole pretreatment.
RESULTS: Nonmalignant mesothelial cells showed no catalase immunoreactivity whereas most mesothelioma cases (24 of 32, 75%) were catalase positive, 17 cases (53%) showing moderate or high expression. Higher catalase expression in mesothelioma was associated with a better prognosis, mean survival rate from diagnosis being 6 and 24 months for negative/low expression and moderate/high expression, respectively. Furthermore, a coordinately high expression of both manganese-superoxide dismutase (Mn-SOD) and catalase predicted even more favorable outcome of the mesothelioma patients. Catalase also could be detected in all mesothelioma cell lines, the most resistant cell line showing the highest protein expression and compartmentalization of catalase mainly to peroxisomes. Aminotriazole inhibition of catalase had a marginal effect on the toxicity caused by epirubicin.
CONCLUSIONS: Catalase may have multifactorial effects in malignant cells; high catalase and/or coordinated high expression of Mn-SOD and catalase may decrease tumor progression by modulating the cellular redox state, but enhanced antioxidant capacity of mesothelioma cells also may protect tumor cells against exogenous oxidants, at least in vitro. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283936     DOI: 10.1002/1097-0142(20010401)91:7<1349::aid-cncr1138>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Effect of Terminalia arjuna on antioxidant defense system in cancer.

Authors:  Nibha Verma; Manjula Vinayak
Journal:  Mol Biol Rep       Date:  2008-06-07       Impact factor: 2.316

2.  Doxorubicin increases intracellular hydrogen peroxide in PC3 prostate cancer cells.

Authors:  Brett A Wagner; Crystal B Evig; Krzysztof J Reszka; Garry R Buettner; C Patrick Burns
Journal:  Arch Biochem Biophys       Date:  2005-08-15       Impact factor: 4.013

Review 3.  Singlet Oxygen, Photodynamic Therapy, and Mechanisms of Cancer Cell Death.

Authors:  Prabal Singh Maharjan; Hitesh Kumar Bhattarai
Journal:  J Oncol       Date:  2022-06-25       Impact factor: 4.501

4.  Catalase immunoexpression in colorectal lesions.

Authors:  Adam Piecuch; Józef Kurek; Marek Kucharzewski; Grzegorz Wyrobiec; Dawid Jasiński; Marlena Brzozowa-Zasada
Journal:  Prz Gastroenterol       Date:  2020-12-10

Review 5.  Metabolic rewiring and redox alterations in malignant pleural mesothelioma.

Authors:  Loredana Urso; Ilaria Cavallari; Evgeniya Sharova; Francesco Ciccarese; Giulia Pasello; Vincenzo Ciminale
Journal:  Br J Cancer       Date:  2019-12-10       Impact factor: 7.640

6.  Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner.

Authors:  Maria Braoudaki; George I Lambrou; Konstantinos Vougas; Kalliopi Karamolegou; George T Tsangaris; Fotini Tzortzatou-Stathopoulou
Journal:  J Hematol Oncol       Date:  2013-07-12       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.